Welcome!

News Feed Item

New Survey Results from The Psoriasis Association Reveal that Significant Improvements Are Still Needed in the Care of Psoriasis Patients to Meet New NICE Recommendations

NORTHAMPTON, England, November 8, 2012 /PRNewswire/ --

New results from a recent survey by The Psoriasis Association reveal that despite progress in the number of patients having their psoriasis severity level assessed, there is still a high level of patient dissatisfaction with treatment, suggesting that these assessments may not be translated into therapy changes where appropriate. Despite an increase in awareness of psoriasis severity measurement, this latest survey also showed that more than half of patients were very dissatisfied with the treatment they were receiving, and over two thirds stated that their doctor or nurse had not discussed any treatment to help improve their quality of life (QoL).[1]

The 'Know your PASI' follow-up survey, which was supported by Janssen, has revealed that patient awareness of Psoriasis Area and Severity Index (PASI) assessments has increased since the first survey in 2011. In fact, the percentage of patients aware of the PASI measurement has nearly trebled to 59%. It is surprising, however, that only 32% of patients have had this important disease severity measurement taken by their doctor. In addition, 63% of patients could not recall their psoriasis severity being measured by any other means, suggesting that they may not be managed effectively as a result.[2]

Helen McAteer, Chief Executive of The Psoriasis Association, says "The survey findings are astonishing and highlight that there has become a need for patients to be proactive in order to drive a change in therapy where they feel they are not receiving the best treatment. We strongly support the need for this change because we see that psoriasis severity assessments are not consistently used or translated into changes in treatment where appropriate."

These findings show a significant disparity between the recommendations being made in the latest National Institute for Health and Clinical Excellence (NICE) guidelines - that all patients should have their disease severity regularly assessed through PASI measurements, and their QoL assessed through the Dermatology Life Quality Index (DLQI), to ensure that they receive the care and treatment they require.[3]Further new findings from the 'Know your PASI' follow-up survey revealed that patients are not being assessed for other key factors such as their cardiovascular risk, which worryingly may mean other conditions and adverse effects of treatment are not being identified.

The government has recognised in a recent framework of care that enhancing QoL for people with long-term conditions is of great importance when considering patient management.[4] The British Association of Dermatologists (BAD) recommends that everyone with psoriasis should have the severity of their disease assessed - taking into consideration where on the body it appears, how widespread it is and the thickness and redness of the plaques. The PASI assessment helps patients and doctors understand the physical severity of the psoriasis and provides a benchmark which, with on-going checks, shows what improvements treatment is making, or crucially, if the treatment is not having the required effect.

Helen McAteer concludes "Based on the new survey findings, The Psoriasis Association is calling for improved awareness of the importance of disease severity, and consequently increased measurement of this in psoriasis patients. We also recommend that to facilitate improved QoL, patients need to proactively request information on different treatments they may eligible for, as soon as their psoriasis severity is deemed great enough for a change in therapy. Patients should feel comfortable speaking up when they are unhappy with their current treatment."

Every person who is passionate about the care provided for patients with psoriasis in the UK is encouraged to sign the Psoriasis Mandate, an online petition calling for improved standards of care in the diagnosis and management of psoriasis. The Psoriasis Association invites signatures to this Mandate, which can be accessed via http://www.psoriasis360.com/psoriasis-mandate to call for support for five key rights of people with psoriasis:

  • Early and accurate diagnosis
  • Access to a specialist for regular treatment review
  • Access to effective treatment options
  • Involvement and choice in a treatment plan with defined goals
  • Understanding and support from society to live a normal life

Estimated to affect up to 1.8 million people in the UK, psoriasis is a painful and debilitating condition characterised by red, raised and inflamed patches on the skin and is classified as being mild, moderate or severe.[5] As well as being physically debilitating, psoriasis can have a deep psychological impact.[6]

Notes to Editors

This press release was funded by Janssen.

About the Psoriasis Area and Severity Index (PASI)

The PASI is a free and simple, painless assessment which takes into account how bad a patient's psoriasis plaques are[7] (how thick, red or sore they are) and how much of the body is affected, to come up with a score. The score is given as a number from 0 (not affected at all) to 72 (very severely affected). If the PASI score is more than 10, the disease is classified as moderate to severe.

Psoriasis is much more than a physical disease and can be considered severe if it has a profound psychological effect on a person's quality of life.  The DLQI is recommended to assess the impact of psoriasis on quality of life.

An interactive PASI calculator (available as an iPhone/iPad app or PC tool) for calculating a PASI score can be downloaded at: http://www.psoriasis360.com/about-psoriasis/types.

About The Psoriasis Association

The Psoriasis Association is the leading national membership organisation for people affected by psoriasis - patients, families, carers and health professionals. Founded in 1968 by Dr Dick Coles, a Consultant Dermatologist in Northampton, the Association has three main aims:

1. To support people who have psoriasis
2. To raise awareness about psoriasis

3. To fund research into the causes, treatments and care of psoriasis

About the Survey

The Know Your PASI Survey is part of a joint collaboration between The Psoriasis Association and Janssen to help educate patients and doctors about how the medical severity of psoriasis is assessed.  The survey was conducted by medeConnect Healthcare Insight, part of the Doctors.net.uk group.

  • Fieldwork for the study was conducted from 4-26 April 2012 with a 5 minute online quantitative survey with 200 psoriasis patients that had participated in the original survey, which took place during 13 July-26 September 2011 and involved 667 respondents, 603 of whom live in the UK, who answered a 5 minute online quantitative survey
  • Recruitment occurred via Psoriasis 360 website and The Psoriasis Association  

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines and metabolic diseases.  Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.  The legal entity of Janssen in the UK and Ireland is Janssen-Cilag Limited.  Please visit http://www.janssen.co.uk for more information.

References:

  1. The Know Your PASI Follow-Up Survey. Data on file. October 2012
  2. The Know Your PASI Survey. Data on file. October 2011
  3. National Institute for Clinical Excellence. Psoriasis. Assessment and management of psoriasis. Clinical Guideline: methods, evidence and recommendations. October 2012
  4. The NHS Outcomes Framework 2012/13. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_131723.pdf . Last accessed October 2012
  5. The Psoriasis Association. Available at: http://www.psoriasis-association.org.uk. Accessed 22 October 2012
  6. Dubertret L et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. British Journal of Dermatology 2006:155:729-36
  7. Mrowietz U et al.  Definition of treatment goals for moderate to severe psoriasis: A European consensus. Archives of Dermatological Research 2011;303:1-10
  8. US National Psoriasis Foundation. Available at http://www.psoriasis.org/about-psoriasis/treatments/severity. Accessed on 22 October 2012.


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
910Telecom exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and exchanges.
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...